Dr. Richard Furman Discusses CLL/SLL Treatments with Lymphoma Research FoundationPosted: October 22, 2015
Recently, CLL Program Director, Dr. Richard Furman discussed CLL/SLL treatment options with the Lymphoma Research Foundation. On the topic of future treatments Dr. Furman spoke about the exciting treatment options in the future:
“This is a critical time for treatment in CLL because we are witnessing a change in treatment paradigms. We are for the first time seeing the opportunity to move completely away from a dependence on chemotherapy. These new treatments are highly effective and well tolerated. Three new treatments that have recently been approved include ibrutinib, idelalisib and obinutuzumab. There are also two second-generation BTK inhibitors that work similar to ibrutinib and are well tolerated that are in the pipeline,” Dr. Furman said. Regarding the new agents, Dr. Furman makes it clear. “Not only are they preferable because they are better tolerated but because they are also far more effective. Going forward, there is an eye toward not only short term toxicities, but also long- term health. As we continue to identify new agents, the possibility of living a long and full life with minimal toxicity is real for CLL/SLL patients, which is exciting.”
The new treatments for CLL/SLL are currently open in clinical trials. You can follow the link to our clinical trials website to see which trials are available for CLL/SLL.